PT  - JOURNAL ARTICLE
AU  - Yeung, Cecilia CS
AU  - Eacker, Stephen M.
AU  - Sala-Torra, Olga
AU  - Beppu, Lan
AU  - Woolston, David W.
AU  - Liachko, Ivan
AU  - Malig, Maika
AU  - Stirewalt, Derek
AU  - Fang, Min
AU  - Radich, Jerald
TI  - Evaluation of Acute Myeloid Leukemia Genomes using Genomic Proximity Mapping
AID  - 10.1101/2024.05.31.24308228
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.31.24308228
4099  - http://medrxiv.org/content/early/2024/06/01/2024.05.31.24308228.short
4100  - http://medrxiv.org/content/early/2024/06/01/2024.05.31.24308228.full
AB  - Background Cytogenetic analysis encompasses a suite of standard-of-care diagnostic testing methods that is routinely applied in cases of acute myeloid leukemia (AML) to assess chromosomal changes that are clinically relevant for risk classification and treatment decisions.Objective In this study, we assess the use of Genomic Proximity Mapping (GPM) for cytogenomic analysis of AML diagnostic specimens for detection of cytogenetic risk variants included in the European Leukemia Network (ELN) risk stratification guidelines.Methods Archival patient samples (N=48) from the Fred Hutchinson Cancer Center leukemia bank with historical clinical cytogenetic data were processed for GPM and analyzed with the CytoTerra® cloud-based analysis platform.Results GPM showed 100% concordance for all specific variants that have associated impacts on risk stratification as defined by ELN 2022 criteria, and a 72% concordance rate when considering all variants reported by the FH cytogenetic lab. GPM identified 39 additional variants, including variants of known clinical impact, not observed by cytogenetics.Conclusions GPM is an effective solution for the evaluation of known AML-associated risk variants and a source for biomarker discovery.Competing Interest StatementSME, MM, and IL are employees of Phase Genomics, Inc. the developers of the technology described in this publication.Funding StatementThis work was supported by an SBIR Phase II grant from NCI/NIH R44CA278140 to SME and Phase Genomics. This work is also partially supported by UG1 CA233338-02, and CA175008-06 to JR at FHCC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institution Review Board of the Fred Hutchinson Cancer Center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made publicly available through dbGAP upon acceptance at a peer-reviewed journal.